Overview

Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

This study involves comparing the effectiveness of treatments in HIV positive patients who may be predisposed to heart attack or stroke. The investigators will evaluate the effectiveness of two drugs, often prescribed by doctors to these patients, at lowering cholesterol and thereby making the patient less them less vulnerable to suffering a heart attack or stroke. The investigators believe that the addition of a second drug, from a different class of cholesterol lowering medications, will improve the outcome of the patients by lowering cholesterol.

Phase:

N/A

Details

Lead Sponsor:

University of British Columbia

Collaborator:

Merck Frosst-Schering Pharma, G.P.

Treatments:

Ezetimibe
Rosuvastatin Calcium